nach oben

Erschienen in:

01.09.2012 | Original Article

The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy

verfasst von: Elvio G. Russi, Marco C. Merlano, Gianmauro Numico, Renzo Corvò, Marco Benasso, Riccardo Vigna-Taglianti, Antonella Melano, Nerina Denaro, Stefano Pergolizzi, Ida Colantonio, Francesco Lucio, Rodolfo Brizio, Umberto Ricardi

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To date, the specific role of “in-field” crusting exudation on pain and on activity of daily living (ADL) in head and neck cancer (HNSCC) patients undergoing treatment with cetuximab and radiochemotherapy has been neglected. The purpose of the study was to evaluate the role of crusting exudation on the severity of pain and ADL

Methods

Thirty-seven of the 45 HNSCC patients enrolled in the alternating radiotherapy, chemotherapy, and cetuximab trial were evaluated in this study. The main radiodermatitis signs (the intensity of erythema, the extension of dry, and moist desquamation and of necrosis)—including crusting exudation severity—pain, ADL, and radiodermatitis scores were registered at least weekly during and after treatment. The correlation between crusting exudation and pain or ADL was evaluated.

Results

The “in-field” crusting exudation score seemed to have the strongest correlation with pain (Spearman’s rho = 0.897; p < 0.001) and the most intense influence on it (Co-B = 0.715; 95% C.I. = 0.643–0.787). However, it seemed to have a weaker correlation with ADL than the other clinical radiodermatitis signs.

Conclusions

Crusts have the strongest correlation with pain in patients with Cetuximab-related radiation dermatitis. Moreover, the presence of crusts can lead operators to misclassify dermatitis as score 4, causing unnecessary delays or interruptions in treatment

Harari PM, Huang S (2001) Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49:427–433PubMedCrossRef

Tejwani A, Wu S, Jia Y et al (2009) Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 115:1286–1299PubMedCrossRef

Woodworth CD, Michael E, Marker D et al (2005) Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 4:650–658PubMedCrossRef

Busam K, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176PubMedCrossRef

Albanell J, Rojo F, Averbuch S et al (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110–124PubMedCrossRef

Budach W, Bolke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514–515PubMedCrossRef

Russi EG, Merlano MC, Comino A, Numico G (2007) Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. AlteRCC Italian Trial): In Regard to Macmillan et al. (Int J Radiat Oncol Biol Phys 2007;68:864–872). Int J Radiat Oncol Biol Phys 69:638–639PubMedCrossRef

Eaby B, Culkin A, Lacouture M (2008) An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 12:283–290PubMedCrossRef

Melosky B, Burkes R, Rayson D et al (2009) Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16:16–26PubMedCrossRef

10.

Pryor DI, Porceddu SV, Burmeister BH et al (2009) Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90:172–176PubMedCrossRef

11.

Merlano M, Russi E, Benasso M et al (2011) Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol 22:712–717PubMedCrossRef

12.

Studer G, Brown M, Salgueiro EB et al (2011) Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent Cetuximab and IMRT. Int J Radiat Oncol Biol Phys 81:110–117PubMedCrossRef

13.

Lee N, Chuang C, Quivey JM et al (2002) Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 53:630–637PubMedCrossRef

14.

Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197PubMedCrossRef

15.

Joshi SS, Ortiz S, Witherspoon JN et al (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916–3923PubMedCrossRef

16.

Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21(11 Suppl 5):34–36

17.

Page DL, Fleming ID, Fritz A et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York

18.

Merlano M, Benasso M, Corvò R et al (1996) Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88:583–589PubMedCrossRef

19.

Common Terminology Criteria for Adverse Events v3.0 (CTCAE), U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute (2006) https://webapps.ctep.nci.nih.gov/webobjs/ctc/webhelp/welcome_to_ctcae.htm. Accessed April 12, 2011

20.

Noble-Adams R (1999) Radiation-induced skin reactions. 2: development of a measurement tool. Br J Nurs 8:1208–1211PubMed

21.

Noble-Adams R (1999) Radiation-induced skin reactions. 3: evaluating the RISRAS. Br J Nurs 8:1305–1312PubMed

22.

MacBride SK, Wells ME, Hornsby C et al (2008) A case study to evaluate a new soft silicone dressing, mepilex lite, for patients with radiation skin reactions. Cancer Nurs 31:E8–E14PubMedCrossRef

23.

Wells M, MacBride S (2004) Radiation skin reactions. In: Faithful S, Wells M (eds) Supportive care in radiotherapy. Churchill Livingstone, Edinburgh, pp 135–159

24.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef

25.

Bölke E, Gerber PA, Lammering G et al (2008) Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184:105–110PubMedCrossRef

26.

Noble-Adams R (1999) Radiation-induced reactions. 1: an examination of the phenomenon. Br J Nurs 8:1134–1140PubMed

27.

Pastore S, Mascia F, Mariotti F et al (2005) ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 174:5047–5056PubMed

28.

Pastore S, Mascia F, Mariani V, Girolomoni G (2008) The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 128:1365–1374PubMedCrossRef

29.

Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v. 4. U.S.Department of Health and Human Services, National Institutes of Health National Cancer Institute (2009) http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed July 10, 2010

30.

Fayers P, Weeden S, Curran D, on behalf of the EORTC Quality of Life Study Group (1998) EORTC QLQ-C30 reference values. EORTC, Brussels

31.

National Cancer Institure, Center for Bioinformatics (2010) CTCAE: redesign and life cycle management. http://evs.nci.nih.gov/ftp1/CTCAE/Documentation/CTCAE_Governance_2010-03-11.pdf. Accessed 19 December 2010

32.

Bernier J, Russi EG, Homey B et al (2011) Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 22:2191–2200PubMedCrossRef

Titel: The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy
verfasst von: Elvio G. Russi
Marco C. Merlano
Gianmauro Numico
Renzo Corvò
Marco Benasso
Riccardo Vigna-Taglianti
Antonella Melano
Nerina Denaro
Stefano Pergolizzi
Ida Colantonio
Francesco Lucio
Rodolfo Brizio
Umberto Ricardi
Publikationsdatum: 01.09.2012
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 9/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1324-4

Neu im Fachgebiet Onkologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy